{
  "docId": "019de071-b6aa-745b-9366-85da01204b7f",
  "docSlug": "36e600bcc4f8cdbd41dc817cb6eec90e",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 91 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 18,
  "pageCount": 91,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes clinical trial data (MOJAVE study) and market opportunity context.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b6aa-745b-9366-85da01204b7f/18",
  "deckHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f",
  "deckJsonHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f.json",
  "deckAnchorHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.56,
        "x": 0.22,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Market Opportunity: >16M Adults in the U.S. have some form of dry eye disease, with meibomian gland dysfunction as a known cause for a majority of these cases⁴",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "499b4bb9-00b2-4c02-aea0-285630ff8b27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.56,
        "x": 0.22,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Second Phase 3 (MOJAVE) Efficacy Endpoints: Total Corneal Staining (sign) and Ocular Dryness (symptom) at Day 57",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19344da5-691c-4917-ad1b-aca920e6aad1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.84,
        "x": 0.08,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Consistent statistically significant efficacy, safety and tolerability have now been demonstrated in both Phase 3 studies of NOV03¹ in patients with dry eye disease associated with meibomian gland dysfunction, as well as in the Phase 2 study. All primary and secondary endpoints were achieved in the Phase 3 program. Anticipate filing NDA with the FDA in 1H22",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26b1e1a7-7bc0-4b9d-ae4d-3615b6f5fd25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.73,
        "x": 0.25,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada. 2. P-value for the difference in Least Squared Means. 3. Intent-to-treat. 4. Sun M, Moreno IY, Dang M, Coulson-Thomas VJ. Meibomian Gland Dysfunction: What Have Animal Models Taught Us? Int J Mol Sci. 2020 Nov 21;21(22):8822. doi: 10.3390/ijms21228822. PMID: 33233466; PMCID: PMC7700490. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700490/.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "422a3c55-eae4-4f23-95ca-56734446c222",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "NOV03¹: Reported Second Phase 3 Topline Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f02b6a8-793b-41f7-9ef4-8229ba78ac08",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 16,
      "beatId": "3301686e-d32a-433b-8780-603c1ac68052",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents growth initiatives and strategic alternatives",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "21cf5b4a-ca72-4285-ac92-38cb6528cb3d",
      "evidence": "The document highlights late-stage programs and recovery in progress",
      "position": 1,
      "objective": "Presenting growth initiatives",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}